21st week of 2021 patent applcation highlights part 23 |
Patent application number | Title | Published |
20210155622 | POLYCYCLIC PYRIDONE DERIVATIVE - The present invention provides a compound represented by the following formula (I): | 2021-05-27 |
20210155623 | PURINE DIONES AS WNT PATHWAY MODULATORS - The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway | 2021-05-27 |
20210155624 | COMPOUND AND PREPARATION AND APPLICATION THEREOF - The present invention discloses a compound, which comprises the structure shown in FIG. | 2021-05-27 |
20210155625 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4, 3-b]INDOLE INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES - 1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones | 2021-05-27 |
20210155626 | MODULATION OF IRE1 - Described herein, inter alia, are compositions and methods of using the same for modulating the activity of Ire1. | 2021-05-27 |
20210155627 | KINASE INHIBITORS AND RELATED METHODS OF USE - The present disclosure is directed to compounds that may selectively inhibit Death Associated Protein Kinases (DAPKs) as well as PIM kinases. The compounds can be used in methods of treating various disorders, including cancers. | 2021-05-27 |
20210155628 | Heterocyclic Compounds as RET Kinase Inhibitors - The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X | 2021-05-27 |
20210155629 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS - Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. | 2021-05-27 |
20210155630 | CRYSTAL OF BENZOXAZOLE DERIVATIVE - Provided are crystals of 1-((2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-7-(thiazol-2-yl)benzo[d]oxazol-4-yl)oxy)-1,1-difluoro-2-methylpropan-2-ol represented by formula (1), | 2021-05-27 |
20210155631 | CARM1 INHIBITORS AND USES THEREOF - Provided herein are compounds of Formula (I): | 2021-05-27 |
20210155632 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 2021-05-27 |
20210155633 | Substituted Pyrrolo,-Furano, and Cyclopentylpyrimidines Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof - The present invention provides substituted pyrrolo-, furano-, and cyclopentylpyrimidine bicyclic pharmaceutical compositions comprising compounds of Formula IV, | 2021-05-27 |
20210155634 | NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME - The present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition including same, wherein the novel tryptophan hydroxylase inhibitor has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or cardiovascular system disorders, related to TPH1 activity. In particular, the novel tryptophan hydroxylase inhibitor has an excellent treatment effect on inflammatory bowel disorders, and thus can be usefully used for the treatment of inflammatory bowel disorder. | 2021-05-27 |
20210155635 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND METHOD USING THE SAME - The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) is shown below: | 2021-05-27 |
20210155636 | Substituted Macrocyclic Compounds and Related Methods of Treatment - The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein. | 2021-05-27 |
20210155637 | Fused Pentacyclic Imidazole Derivatives - A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof. | 2021-05-27 |
20210155638 | RAW MATERIAL FOR FORMING THIN FILM BY ATOMIC LAYER DEPOSITION METHOD AND METHOD FOR PRODUCING THIN FILM - Provided is a thin-film forming raw material, which is used in an atomic layer deposition method, including a magnesium compound represented by the following general formula (1): | 2021-05-27 |
20210155639 | THIOPHOSPHATE AND PHOSPHINE SULFIDE DERIVATIZED MONOMERS AND POLYMERS FOR VOLUME BRAGG GRATINGS - The disclosure provides recording materials including thiophosphate derivatized monomers and polymers for use in volume Bragg gratings, including, but not limited to, volume Bragg gratings for holography applications. Several structures are disclosed for thiophosphate derivatized monomers and polymers for use in Bragg gratings applications, leading to materials with higher refractive index, low birefringence, and high transparency. The disclosed thiophosphate derivatized monomers and polymers thereof can be used in any volume Bragg gratings materials, including two-stage polymer materials where a matrix is cured in a first step, and then the volume Bragg grating is written by way of a second curing step of a monomer. | 2021-05-27 |
20210155640 | LINOLEIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION OR FOOD COMPOSITION COMPRISING SAID LINOLEIC ACID DERIVATIVES, AND THEIR USES - Disclosed is a linoleic acid derivative of Formula (I) below including a hydrophobic part C | 2021-05-27 |
20210155641 | METHOD FOR PRODUCING PHOSPHINOBENZENE BORANE DERIVATIVE, METHOD FOR PRODUCING 1,2-BIS(DIALKYLPHOSPHINO)BENZENE DERIVATIVE, AND TRANSITION METAL COMPLEX - A method for producing a phosphinobenzene borane derivative comprises a reaction step (A) of obtaining liquid A containing a 1,2-dihalogenobenzene represented by the following general formula (1): | 2021-05-27 |
20210155642 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE - This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin. | 2021-05-27 |
20210155643 | DEUTERATED PYRIDONE AMIDES AND PRODRUGS THEREOF AS MODULATORS OF SODIUM CHANNELS - Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. The compounds have the formula (I) wherein R is H or CH | 2021-05-27 |
20210155644 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF - An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides an anti-adenoviral agent including a compound represented by General Formula [1] | 2021-05-27 |
20210155645 | ENHANCING CD8+ T CELLS FOR ADOPTIVE T CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP) - The invention encompasses ex vivo method of stimulating isolated memory T-cell, tumor-infiltrating lymphocyte (TIL), T cell receptor (TCR) engineered cell, and/or chimeric antigen receptor (CAR) engineered cell with compounds of Formula I below, which are inhibitors of the TC-PTP enzyme. | 2021-05-27 |
20210155646 | Rhenium Complexes and Methods of Use - Halide ligand free rhenium complexes are described as well as methods for depositing rhenium-containing films. Some embodiments provide a rhenium complex with a general formula of O | 2021-05-27 |
20210155647 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND - Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound: | 2021-05-27 |
20210155648 | OLEFIN METATHESIS CATALYSTS - This invention relates generally to olefin metathesis catalyst compounds, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, articles of manufacture comprising such compounds, and the use of such compounds in the metathesis of olefins and olefin compounds. The invention has utility in the fields of catalysts, organic synthesis, polymer chemistry, and industrial and fine chemicals industry. | 2021-05-27 |
20210155649 | ULTRA-THIN NI-FE-MOF NANOSHEET, PREPARATION METHOD AND USE THEREOF - The present invention discloses a method for preparing an ultra-thin Ni—Fe-MOF nanosheet, which comprises the steps of dissolving an organic ligand in an organic solvent, dripping the resulting solution to an aqueous solution containing a nickel salt and an iron salt, mixing uniformly and reacting at 140-160° C. for 3-6 h to obtain the ultra-thin Ni—Fe-MOF nanosheet, wherein the organic ligand is terephthalic acid and/or disodium terephthalate, and the organic solvent is N,N-dimethylacetamide and/or N,N-dimethylformamide. The present invention discloses an ultra-thin Ni—Fe-MOF nanosheet, and use thereof. The preparation method does not require a surfactant, the surface of the product is neat and easy to be cleaned, and the large-scale synthesis of 2D ultra-thin MOF materials can be realized. | 2021-05-27 |
20210155650 | CONFINED PORPHYRIN CO(II) AND PREPARATION METHOD AND APPLICATION THEREOF - A confined porphyrin Co(II), which is prepared by the following method: Equimolar amounts of aromatic aldehyde and pyrrole are condensed under acidic conditions to synthesize phenyl porphyrin compounds; the phenyl porphyrin compounds are metallized in a chloroform-methanol solution to obtain porphyrin Cu(II), which is brominated and demetallized to obtain confined porphyrin; the confined porphyrin is stirred and refluxed in a methanol solution for 12.0-24.0 h to obtain confined porphyrin Co(II). Its application is as follows: The confined porphyrin Co(II) is dissolved in cycloalkanes; the reaction system is sealed, and heated to 100 to 130° C. with stirring, to which oxygen is introduced to 0.2 to 3.0 MPa; the reaction is carried out for 3.0 to 24.0 h with stirring with the set temperature and oxygen pressure being maintained; and then the reaction solution is subjected to post-treatment to obtain the products. | 2021-05-27 |
20210155651 | PROCESS FOR THE PREPARATION OF IRON (III) CARBOXYMALTOSE - Water soluble iron carbohydrate complex obtainable from an aqueous solution of iron (III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous oxone solution at a pH-value within the alkaline range, where, when one maltodextrin is present, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is present, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency anaemia conditions. | 2021-05-27 |
20210155652 | TLR7 AGONISTS - The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease. | 2021-05-27 |
20210155653 | METHOD FOR HOMOGENIZING BILE ACID DERIVATIVES - The present invention relates to a process for producing bile acid derivatives having a protected hydroxyl group in the 3 position comprising contacting a bile acid derivative having an unprotected 3-alpha-hydroxyl group with a specific lipase. The present invention further relates to a bile acid derivative obtained or obtainable by the process, to the use of the bile acid derivative obtained or obtainable by the process for producing lithocholic acid and also to a process for producing lithocholic acid and to lithocholic obtained by the process. The invention further relates to the use of lithocholic acid obtained or obtainable by the process for producing ursodeoxycholic acid or ursodeoxycholic acid derivatives. | 2021-05-27 |
20210155654 | CLEAVABLE LINKER FOR PEPTIDE SYNTHESIS - The present invention provides a new building block for peptide synthesis, which introduces a cleavage site that can be used to generate cleavable fragments subsequent to a peptide sequence. | 2021-05-27 |
20210155655 | Method for purifying PEGylated erythropoietin - Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange Toyopearl® SP-650 chromatography material and employing a second wash step with an increased pH value compared to the first wash step a fusion protein of erythropoietin and a single poly (ethylene glycol) residue can be obtained in a single step with high purity and yield and suitability for large scale applications. | 2021-05-27 |
20210155656 | Methods for purification of polypeptides using polysorbates - Herein is reported a method for purifying a protein from a sample comprising the protein and at least one impurity with hydrolytic activity, comprising the following steps:
| 2021-05-27 |
20210155657 | SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE - A method of isolating and separating a target macromolecule, such DNA (double stranded or single stranded), RNA (double stranded or single stranded), messenger RNA, or other oligonucleotide or oligonucleoside, from a sample by binding the target macromolecule to an affinity ligand that is bound to a surface is disclosed. The method may be employed in chromatography or any other of the separation sciences. | 2021-05-27 |
20210155658 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS - Useful chiral specific boron-containing compounds, such as boronate, boronate esters, boranamines, borane diamines, boranamine thioesters, and boronic mono/di-thioesters, have been prepared. These compounds and compositions containing them are useful as anti-cancer or anti-amyloidosis agents. | 2021-05-27 |
20210155659 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS - The present invention relates to synthetic polypeptide compounds which bind to a class A G-protein-coupled receptor, the Apelin receptor. These compounds may act as apelin receptor antagonists. These compounds and compositions comprising them may be useful in the treatment of diseases, such as cancer. | 2021-05-27 |
20210155660 | RATIONALLY DESIGNED VIRUS-LIKE PARTICLES FOR MODULATION OF CHIMERIC ANTIGEN RECEPTOR (CAR)-T-CELL THERAPY - The present invention relates to a modified viral structural protein (VSP) as a tool for specifically targeting a chimeric antigen receptor (CAR) expressed on cells of the immune system. The modified VSPs can assemble into virus like particles (VLP). Exposed areas of the VSPs are modified to comprise in a region located atthe surface of a higher order structure, e.g. such as a capsomeric structure, a capsid, a VLP, a viral vector or a virus, a ligand specifically binding to a CAR (LCAR). The present invention thus, provides a modified VSP. The invention also relates to a nucleic acid encoding said VSP. Further, the invention relates to a capsomeric structure, a capsid, a VLP, a viral vector or a virus comprising at least one VSP. Further, the invention relates to a pharmaceutical composition comprising the VSP, the nucleic acid, the capsomeric structure, the capsid, the VLP, the viral vector or the virus comprising at least one VSP. Further, the invention relates to a VSP, a capsomeric structure, a capsid, a VLP, a viral vector or a virus for use in medicine, in particular for use in decreasing or limiting an immune response, treating or preventing tumor lysis syndrome or for treating an immune disease in a patient. | 2021-05-27 |
20210155661 | INSECTICIDAL PROTEINS - Compositions and methods for controlling plant pests are disclosed. In particular, novel engineered hybrid insecticidal proteins having toxicity to at least European corn borer are provided. By fusing unique combinations of complete or partial variable regions and conserved blocks of at least two different | 2021-05-27 |
20210155662 | MYC NUCLEIC ACIDS AND USES THEREOF - Disclosed herein are molecules and pharmaceutical compositions that mediate RNA interference against MYC. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that mediate RNA interference against MYC. | 2021-05-27 |
20210155663 | MESENCHYMAL STEM CELLS EXPRESSING BRAIN-DERIVED NEUROTROPHIC FACTOR AND USE THEREOF - The present invention relates to; a recombinant lentivirus comprising a gene encoding brain-derived neurotrophic factor (BDNF) protein; and a mesenchymal stem cell transformed with the lentivirus; and a method for mass-producing a cell therapeutic agent expressing BDNF protein using the same. The mesenchymal stem cell transformed with the recombinant lentivirus of the present invention can regulate the timing of expression of BDNF protein, maintain a high cell proliferation rate and overexpress a BDNF protein, and are excellent in safety. Therefore, a mesenchymal stem cells transfected with the lentivirus may be used for the treatment of various neurological diseases as a stein cell therapeutic agent capable of being mass-produced and maintaining the same effect. | 2021-05-27 |
20210155664 | REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF NEUROLOGICAL DISORDERS - This document provides methods and materials involved in treating mammals having a neurological disorder in the brain (e.g., Alzheimer's disease). For example, methods and materials for administering a composition including exogenous nucleic acid encoding a NeuroD1 polypeptide to a mammal having a neurological disorder in the brain are provided. | 2021-05-27 |
20210155665 | METHOD FOR PREPARING INTERLEUKIN-2 OR INTERLEUKIN-2 ANALOGUES - A method for preparing interleukin-2 or an interleukin-2 analogue formed by at least three building blocks includes: synthesizing the at least three building blocks, whereby for each building block the C-terminal residue comprises an α-keto group and/or the N-terminal residue comprises a cyclic hydroxylamine; coupling the at least three building blocks by KAHA ligation resulting in a depsipeptide; and rearranging the depsipeptide to obtain interleukin-2 or an interleukin-2 analogue. | 2021-05-27 |
20210155666 | ANALOGUES OF PARATHYROID HORMONE (1-34) THAT FUNCTION AS AGONISTS OF THE PARATHYROID HORMONE RECEPTOR-1 AND DISPLAY MODIFIED ACTIVITY PROFILES - Described are polypeptide analogs of parathyroid hormone (PTH) that include an unnatural amino acid substitution at positions 7 or 8 from the N-terminus of the polypeptide. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism. | 2021-05-27 |
20210155667 | USE OF GENE EDITING TO GENERATE UNIVERSAL TCR RE-DIRECTED T CELLS FOR ADOPTIVE IMMUNOTHERAPY - The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided. | 2021-05-27 |
20210155668 | CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF - Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided. | 2021-05-27 |
20210155669 | CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF - Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided. | 2021-05-27 |
20210155670 | SYSTEMS AND METHODS FOR THE PREPARATION OF PEPTIDE-MHC-I COMPLEXES WITH NATIVE GLYCAN MODIFICATIONS - Disclosed herein are novel glycosylated peptide receptive MHC-I complexes that allow for efficient production of glycosylated MHC-I multimers. Such glycosylated peptide receptive MHC-I complexes include a single-chain MHC-I construct and are produced in mammalian expression systems (e.g., CHO and HEK cells) that allow for the glycosylation of the complexes at one or more native positions. Multimers (e.g., tetramers) produced from the glycosylated peptide receptive MHC-I complexes provided herein advantageously allow for the identification of high-affinity T cell and natural killer cell receptors previously unidentified using traditional unglycosylated MHC tetramers. | 2021-05-27 |
20210155671 | USES OF CD20-BINDING MOLECULES AND ADDITIONAL THERAPEUTIC AGENTS - Provided herein are uses of CD20-binding molecules and one or more additional therapeutic agents. Certain CD20-binding molecules useful in the methods disclosed herein comprise 1) two or more CD20 binding regions and 2) one or more Shiga toxin effector polypeptides derived from an A Subunit of a member of the Shiga toxin family. Also disclosed herein are uses of CD20-binding molecules, and compositions thereof, (such as in conjunction with one or more additional therapeutic agents) for selective killing of specific cell types (such as a CD20-expressing tumor cell) and/or treating a variety of conditions, including cancers and tumors involving a CD20-expressing cell. | 2021-05-27 |
20210155672 | METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING INEFFECTIVE ERYTHROPOIESIS - In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof. Subjects in need include, for example, subject having an anemia and subjects have an ineffective erythropoiesis disorder. | 2021-05-27 |
20210155673 | HETERODIMERS OF SOLUBLE INTERFERON RECEPTORS AND USES THEREOF - The present disclosure provides soluble interferon receptors. The methods of the disclosure can be used to treat or prevent a condition associated with an abnormal immune response. | 2021-05-27 |
20210155674 | FACTOR IX-TRANSFERRIN FUSION PROTEINS - The invention relates to fusions of coagulation Factor IX (FIX) and transferrin (Tf). These FIX-Tf fusion proteins can be administered orally, and are capable of reaching the systemic circulation by utilizing an endocytosis-dependent mechanism to cross the gut epithelium. Upon delivery of FIX-Tf fusion proteins to the systemic circulation, the fusion proteins are useful for treating bleeding disorders, such as haemophilia B. | 2021-05-27 |
20210155675 | Mutant Cytochrome Protein and Use Thereof - A mutant cytochrome protein originated from a cytochrome protein having three heme-binding domains, which mutant cytochrome protein lacks the first heme-binding domain and the second heme-binding domain as counted from the N-terminus, is provided. The mutant cytochrome protein may lack a region(s) containing the first and second heme-binding domains. | 2021-05-27 |
20210155676 | HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES - The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof. | 2021-05-27 |
20210155677 | ENGINEERED MICROBE-TARGETING MOLECULES AND USES THEREOF - Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface. Microbe-targeting molecules and/or substrates can be regenerated after use by washing with a low pH buffer or buffer in which calcium is insoluble. | 2021-05-27 |
20210155678 | Methods and Compositions Related to Immunizing Against Staphylococcal Lung Diseases and Conditions - Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing Hla to provide immunoprotection against | 2021-05-27 |
20210155679 | THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS - The disclosure provides for methods and treatments of TLR2-mediated diseases and disorders comprising administering an antibody, antibody fragment, or polypeptide that binds to and inhibits the biological activity of oxidized phospholipids. | 2021-05-27 |
20210155680 | ANTIBODY THAT SPECIFICALLY RECOGNIZES N TERMINUS OF APP669-x, AND IMMUNOASSAY METHOD - The present invention provides an antibody that recognizes peptides the N-terminals of which start from APP669 (collectively referred to as APP669-x) including the peptide APP669-711 related to an amyloid β (Aβ); a method for measuring APP669-x using said antibody; and a sandwich immunoassay method that is capable of detecting and quantifying a polypeptide to be analyzed with a high sensitivity. An APP669-x N-terminal-recognizing monoclonal antibody that specifically recognizes an N-terminal of an APP669-x peptide. An immunoassay method that uses an APP669-x N-terminal-recognizing monoclonal antibody that specifically recognizes an N-terminal of an APP669-x peptide, and comprises reacting an APP669-x in a sample with the APP669-x N-terminal-recognizing monoclonal antibody to measure the APP669-x. | 2021-05-27 |
20210155681 | COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS - Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders. | 2021-05-27 |
20210155682 | COMPOSITIONS AND METHODS FOR REDUCTION OF LIPOPROTEIN A FORMATION AND TREATMENT OF AORTIC VALVE SCLEROSIS AND AORTIC STENOSIS - Compositions and methods to reduce the formation of lipoprotein(a) are provided, thereby reducing the risk of aortic stenosis or aortic valve sclerosis. Antibodies or antigen-binding fragments thereof capable of binding apolipoprotein B | 2021-05-27 |
20210155683 | MONOCLONAL ANTIBODY OF NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOF - The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody against nerve growth factor of the present invention comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody against nerve growth factor of the present invention can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and to prepare a drug for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value. | 2021-05-27 |
20210155684 | Antibody Formulations - Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations. | 2021-05-27 |
20210155685 | IL-1Beta Neutralizing Human Monoclonal Antibodies - The present invention is directed to antigen binding proteins and in particular to IL-1β antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production. | 2021-05-27 |
20210155686 | IL-1Beta Neutralizing Human Monoclonal Antibodies - The present invention is directed to antigen binding proteins and in particular to IL-1β antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production. | 2021-05-27 |
20210155687 | DOSAGE REGIMEN - The present invention provides pharmaceutical compositions comprising antigen binding proteins that specifically bind Oncostatin M (OSM) and in particular human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor, novel therapeutic regimens for said pharmaceutical compositions; and methods for administering said pharmaceutical compositions in the treatment of an inflammatory or autoimmune disorder, in particular in the treatment of systemic sclerosis. | 2021-05-27 |
20210155688 | ANTI-FOLR1 IMMUNOCONJUGATE DOSING REGIMENS - Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects. | 2021-05-27 |
20210155689 | ANTI-HUMAN LAG-3 MONOCLONAL ANTIBODY AND USE THEREOF - Disclosed in the present invention are an antibody targeting LAG-3, a preparation method therefor and the use thereof. In particular, disclosed in the present invention is a novel monoclonal antibody targeting LAG-3. Also disclosed in the present invention is a method for the preparation of the monoclonal antibody. The monoclonal antibody of the present invention is capable of binding LAG-3 antigens with high specificity, and has very high affinity and significant activities such as anti-tumor activity. | 2021-05-27 |
20210155690 | COMPOSITIONS AND METHODS FOR THE IMMUNE CHECKPOINT BLOCKADE OF TIM4 - Compositions and methods are provided for blocking Tim4 on the surface of myeloid cells in order to treat and prevent cancer in a subject. Blocking Tim4 on the surface of myeloid cells can restore anti-tumor immunity and reduce the uptake of apoptotic cells. Further, by administering an anti-Tim4 antibody, the pro-inflammatory anti-tumor response can be increased. Accordingly, methods for reducing the uptake of apoptotic cells and methods for increasing anti-tumor immunity are provided herein. The present disclosure further describes a method for producing monoclonal antibodies that bind Tim4 on the surface of myeloid cells. The anti-Tim4 antibodies can further be selected for their ability to inhibit engulfment of dead or dying cells, to elicit the production of inflammatory cytokines, and to restrict the growth of tumors. | 2021-05-27 |
20210155691 | METHODS OF PREVENTING OR TREATING NON-HEMATOPOIETIC SLAMF7 POSITIVE AND SLAMF7 NEGATIVE CANCERS - A method for the prevention and/or treatment of a neoplastic disease comprising a solid tumor in a subject in need thereof, said method comprising administering an effective amount of a signal regulatory protein alpha (SIRPalpha)-cluster of differentiation 47 (CD47) checkpoint inhibitor or a composition comprising the inhibitor, and a pharmaceutically acceptable carrier, to a subject having solid tumor cells expressing signaling lymphocytic activation molecule family member 7 (SLAMF7) and CD47. | 2021-05-27 |
20210155692 | ANTI-ROR ANTIBODY CONSTRUCTS - Anti-ROR antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented. | 2021-05-27 |
20210155693 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY - Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce. | 2021-05-27 |
20210155694 | Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease - The present invention is directed to DA×CD3 Binding Molecules comprising a vCD3-Binding Domain, which comprises a CDRHI Domain, a CDRH2 Domain, a CDRH3 Domain, a CDRL I Domain, a CDRL2 Domain, and a CDRL3 Domain, at least one of which differs in amino acid sequence from the amino acid sequence of the corresponding CDR of a rCD3-Binding Domain, wherein the DA×CD3 Binding Molecule comprising such vCD3-Binding Domain exhibits an altered affinity for CD3, relative to a DA×CD3 Binding Molecule comprising such rCD3-Binding Domain. The invention particularly concerns to such DA×CD3 Binding Molecules comprising a vCD3-Binding Domain which exhibit reduced affinity for CD3 and are capable of mediating redirected killing of target cells expressing a DA and exhibit lower levels of cytokine release relative to a DA×CD3 Binding Molecule comprising a rCD3-Binding Domain. The invention particularly concerns the use of DA×CD3 Binding Molecules comprising a vCD3-Binding Domain in the treatment of cancer and pathogen-associated diseases. The present invention is also directed to pharmaceutical compositions that comprise such molecule(s). | 2021-05-27 |
20210155695 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of targeted therapy to treat cancer (e.g., prostate cancer) in subjects with CDK12 mutations. | 2021-05-27 |
20210155696 | ENHANCING THE THERAPEUTIC ACTIVITY OF IMMUNE CHECKPOINT INHIBITOR - The present invention provides antagonists and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases. | 2021-05-27 |
20210155697 | ANTIBODIES DIRECTED TO TIE-2 AND METHODS OF USE - The invention relates to anti-Tie2 antibodies and methods of using the same. | 2021-05-27 |
20210155698 | ANTIBODIES THAT BIND EGFR AND ERBB3 - The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 p M for inhibiting EGER and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC 3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies. | 2021-05-27 |
20210155699 | ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION - The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed. | 2021-05-27 |
20210155700 | ANTI-DEspR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY - Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anto-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments. | 2021-05-27 |
20210155701 | POLYPEPTIDE COMPRISING IL-1R1 BINDING DOMAIN AND CARRYING MOIETY - The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for an antigen binding domain whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including an antigen binding domain whose antigen binding activity is inhibited by associating with particular VL, VH or VHH. | 2021-05-27 |
20210155702 | ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOF - The invention relates to a T cell expressing an antibody or comprising the coding sequence of the antibody or an expression vector thereof; the antibody contains an optional signal peptide, an antigen binding sequence and a mutant type Fc segment, wherein the mutant type Fc segment is a Fc segment in which amino acid residues at the 17th site and the 79th site of the IgG4 Fc segment shown by SEQ ID NO: 25 are mutated into E and Q respectively. Preferably, the T cell is a CAR-T cell. The present invention further relates to a treatment application of the T cell in malignant tumors. | 2021-05-27 |
20210155703 | ANTI-CD27 ANTIBODIES AND USES THEREOF - This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody. | 2021-05-27 |
20210155704 | HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS - The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising V | 2021-05-27 |
20210155705 | ANTI-CD40 ANTIBODIES AND USES THEREOF - This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof. | 2021-05-27 |
20210155706 | MONOCLONAL ANTIBODY TARGETING A UNIQUE SIALOGLYCOSYLATED CANCER-ASSOCIATED EPITOPE OF CD43 - The present invention relates to a monoclonal mouse antibody produced by the hybridoma cell deposited under ICLC accession number ICLC PD no 16001. Furthermore, the invention relates to an antibody comprising a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3, and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3, wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences GFTFSSFGMH (SEQ ID NO: 1), YISSGSGNFYYVDTVKG (SEQ ID NO: 43), STYYHGSRGAMDY (SEQ ID NO: 3), SASSSVSSMYWY (SEQ ID NO: 4), DTSKMAS (SEQ ID NO: 5), and QQWSSYPPIT (SEQ ID NO: 6), respectively. In addition, the invention relates to antibodies recognizing the same epitope. | 2021-05-27 |
20210155707 | ANTI-SIRPalpha ANTIBODY - An anti-SIRPα antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRPα to inhibit binding of human SIRPα to CD47. | 2021-05-27 |
20210155708 | COMBINATION THERAPIES AGAINST CANCER TARGETING CD38 AND TGF-BETA - The present disclosure relates to combination cancer therapies targeting CD38 and TGF-β using antibodies specific for these targets. Also provided are compositions useful in the therapies. | 2021-05-27 |
20210155709 | ANTIBODIES ANTI TUMOR ASSOCIATED ANTIGENS AND METHOD FOR OBTAINING THEM - The present disclosure refers to a method for identifying an immunoglobulin, recombinant or synthetic antigen-binding fragments thereof that present in vivo tumor binding activity and do not significantly cross-react with normal cells and to antibodies thereby obtained and to medical uses thereof | 2021-05-27 |
20210155710 | MODULATING ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS - Provided herein are methods of modulating Antibody Dependent Cellular Phagocytosis (ADCP) activity of an antibody composition. In exemplary embodiments, the method comprises modulating the amount of (a) galactosylated glycans of the antibody, (b) afucosylated glycans of the antibody, (c) high mannose glycans of the antibody, or (d) a combination thereof, to modulate ADCP activity of the antibody, as further described herein. | 2021-05-27 |
20210155711 | Antibody Fc Mutants with Ablated Effector Functions - Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders. | 2021-05-27 |
20210155712 | TREATMENT AND PREVENTION OF CANCER USING HER3 ANTIGEN-BINDING MOLECULES - Methods for treating or preventing a cancer in a subject are disclosed, wherein the cancer comprises cells having a mutation resulting in increased expression of a ligand for HER3, wherein the method comprises administering a therapeutically or prophylactically effective amount of an antigen-binding molecule which is capable of binding to HER3 to the subject. | 2021-05-27 |
20210155713 | ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES - Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies. | 2021-05-27 |
20210155714 | Hybridoma Cell Strain and Monoclonal Antibody Produced Therefrom Against Serine Protease of Trichinella Spiralis in Intestinal Stage and Application Thereof - A hybridoma cell stain and a monoclonal antibody secreted therefrom and application thereof belong to the technical field of prevention and treatment of | 2021-05-27 |
20210155715 | USE OF TRYPTOPHAN DERIVATIVES AND L-METHIONINE FOR PROTEIN FORMULATION - The present disclosure provides methods and formulations comprising a polypeptide comprising solvent accessible amino acid residues susceptible to oxidation wherein N-acetyl-DL-tryptophan (NAT) and/or L-methionine is used to prevent oxidation of the polypeptide. | 2021-05-27 |
20210155716 | Cellulose Derivatives - The present description is related to methods for derivatizing cellulose pulp, and to products obtainable using said method. | 2021-05-27 |
20210155717 | POWDER CONTAINING CARBOXYMETHYLATED CELLULOSE NANOFIBERS - A powder that contains carboxymethylated cellulose nanofibers, said carboxymethylated cellulose nanofibers having a degree of carboxymethyl substitution of 0.50 or less and a cellulose type I crystallinity of 60% or more, and has a median diameter of 10.0 μm to 150.0 μm. This powder is suitable usable as an additive. | 2021-05-27 |
20210155718 | BABASSU BLEACHING PROCESS - The present invention relates to a novel process for bleaching babassu, preferably from the species | 2021-05-27 |
20210155719 | OXIDIZED DEXTRAN - Compositions comprising oxidized dextran compounds are disclosed herein. Oxidized dextran compounds are produced by contacting dextran under aqueous conditions with at least one N-oxoammonium salt, at least one periodate compound, and/or at least one peroxide compound. | 2021-05-27 |
20210155720 | Method for Preparing Hyaluronan Odd-numbered Oligosaccharides by Double Enzyme Hydrolysis - The disclosure discloses a method for preparing hyaluronan oligosaccharides with odd-numbered degrees of polymerization by hydrolysis, and belongs to the technical field of biological engineering. The disclosure takes macromolecular hyaluronic acid as the substrate, and by controlling the addition amount and reaction time of two hyaluronic acid hydrolases, leech hyaluronidase (LHase) and bovine testicular hyaluronidase (BTH), simultaneously prepares two different structures of hyaluronan oligosaccharides with odd-numbered degrees of polymerization (trisaccharide, pentasaccharide and heptasaccharide). The disclosure provides a new, simple and feasible method for preparing hyaluronan oligosaccharides with odd-numbered degrees of polymerization, thereby laying a foundation for the research on the functions and characteristics of the hyaluronan oligosaccharides with odd-numbered degrees of polymerization. | 2021-05-27 |
20210155721 | AQUEOUS POLYMER DISPERSION AND PREPARATION METHOD THEREOF - The present invention relates to an aqueous polymer dispersion containing a multistage emulsion polymer particle. The multistage emulsion polymer particle contains a polysiloxane formed in the first stage; a transition layer formed in the second stage; and a polyacrylate formed in the third stage. The transition layer is made of silane coupling agents. The present invention also relates to a method of preparing the aqueous polymer dispersion and use of the aqueous polymer dispersion for preparing coatings. | 2021-05-27 |